Thursday, July 21, 2005 7:45:23 PM
before the deal is done, there were 6.8 mil shares o\s of GEIV. 2 dudes owned 5.3 mil & there were 1.5 mil shares owned by "others". the 1.5 mil shares were issued in exchange for $37,500...quite a deal. Then the 8K got issued so that the share structure of GEIV becomes:
As a result of the foregoing, following the Closing the capitalization of GEIV is anticipated to be as follows:
Shares
% of Total
Owned by current GEIV officers and directors
50,000
0.52%
Owned by GEIV shareholders
1,500,000
15.45%
Owned by NowAuto
8,157,661
84.03%
Total Issued and Outstanding GEIV common stock
9,707,661
100.00%
Pursuant to the asset purchase agreement, at closing, GEIV shall issue to NowAuto 8,157,661 shares of its common stock, representing 84.03% of the outstanding GEIV common stock upon consummation of the Agreement, in exchange for all of the assets of NowAuto. The consideration set forth in the Agreement was determined as a result of arm's-length negotiations between the parties.
Looks to me that NWAU is selling all their assets & liabilities to GEIV in return for 8,157,661 or 84.03% of GEIV. NWAU I guess becomes an inactive holdco with an operating sub GEIV which will carry out all the business that NWAU previously carried out.
As a result of the foregoing, following the Closing the capitalization of GEIV is anticipated to be as follows:
Shares
% of Total
Owned by current GEIV officers and directors
50,000
0.52%
Owned by GEIV shareholders
1,500,000
15.45%
Owned by NowAuto
8,157,661
84.03%
Total Issued and Outstanding GEIV common stock
9,707,661
100.00%
Pursuant to the asset purchase agreement, at closing, GEIV shall issue to NowAuto 8,157,661 shares of its common stock, representing 84.03% of the outstanding GEIV common stock upon consummation of the Agreement, in exchange for all of the assets of NowAuto. The consideration set forth in the Agreement was determined as a result of arm's-length negotiations between the parties.
Looks to me that NWAU is selling all their assets & liabilities to GEIV in return for 8,157,661 or 84.03% of GEIV. NWAU I guess becomes an inactive holdco with an operating sub GEIV which will carry out all the business that NWAU previously carried out.
Recent FITY News
- Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health • ACCESS Newswire • 04/15/2026 12:30:00 PM
- Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • GlobeNewswire Inc. • 01/05/2026 06:08:59 PM
- Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • InvestorsHub NewsWire • 01/05/2026 06:00:00 PM
- Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer • GlobeNewswire Inc. • 10/09/2025 02:23:35 PM
- Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer • InvestorsHub NewsWire • 10/09/2025 02:00:00 PM
- Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. • GlobeNewswire Inc. • 09/30/2025 01:56:45 PM
- Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. • InvestorsHub NewsWire • 09/30/2025 01:45:00 PM
- Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB • GlobeNewswire Inc. • 09/23/2025 01:07:25 PM
- Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB • InvestorsHub NewsWire • 09/23/2025 12:35:36 PM
- Fifty1 Labs, Inc. Leadership Publishes Landmark Framework to Unlock Global Oncology Data Through AI-Driven Real-World Evidence • InvestorsHub NewsWire • 09/04/2025 12:30:00 PM
- Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032 • InvestorsHub NewsWire • 08/26/2025 01:00:00 PM
- Fifty1 Labs, Inc. Subsidiary Fifty1 AI Labs Partners with ViRx@Stanford Under 'BE READI!' Initiative to Advance AI-Powered Antiviral Drug Repurposing • InvestorsHub NewsWire • 08/22/2025 02:30:00 PM
- Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment Pathways to Accelerate Functional Medicine Innovation • InvestorsHub NewsWire • 08/12/2025 12:30:00 PM
- Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference, Showcasing AI-Driven Functional Medicine Strategy and World-Class Leadership • InvestorsHub NewsWire • 07/29/2025 01:00:00 PM
- Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières • InvestorsHub NewsWire • 07/28/2025 12:30:00 PM
- Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies • InvestorsHub NewsWire • 07/17/2025 12:30:00 PM
- Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • InvestorsHub NewsWire • 07/10/2025 12:30:49 PM
- Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • InvestorsHub NewsWire • 07/08/2025 12:30:00 PM
